The tyrosine kinase inhibitor crizotinib is an effective therapy for patients with cancers harboring rearrangements of the anaplastic lymphoma kinase (ALK) gene. Here, we describe two patients with advanced ALK-positive lung cancer who developed hypersensitivity to crizotinib, requiring temporary discontinuation of the drug. Both patients were treated with a rapid oral desensitization protocol allowing them to resume crizotinib without further signs or symptoms of hypersensitivity.
CITATION STYLE
Awad, M. M., Lax, T. P., Slawski, B. R., & Shaw, A. T. (2014). Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib. Journal of Thoracic Oncology, 9(11), 1726–1728. https://doi.org/10.1097/JTO.0000000000000350
Mendeley helps you to discover research relevant for your work.